Florida AG Probes CVS for Alleged Anticompetitive Pharmacy Practices

Florida Attorney General James Uthmeier has launched an investigation into CVS Health, raising concerns about potential anticompetitive practices that could harm consumers and independent pharmacists. The probe aims to uncover whether the vertically integrated healthcare giant is favoring its own pharmacies over competitors, a move that could undermine fair competition and access to affordable medications.

CVS Health, which operates one of the largest pharmacy benefit managers (PBMs) in the country through Caremark, as well as thousands of retail pharmacies, including about 800 in Florida, faces scrutiny over allegations of unfair business practices. Uthmeier's office has issued a subpoena demanding extensive documentation and sworn testimony by July 28.

The Scope of the Investigation

The Attorney General’s office is seeking detailed information on reimbursement rates, pharmacy contracts, patient steering, audits, rebates, and differential treatment between CVS-owned and independent pharmacies. Uthmeier is particularly interested in whether CVS is using its position to steer patients toward its own locations or reimbursing them at higher rates than independent competitors.

“Florida families and seniors deserve access to affordable medication and real pharmacy choices-not a system rigged by one giant corporation that may favor its own stores and squeeze out competitors,” Uthmeier stated. The investigation aims to ensure that the market remains fair and competitive, benefiting consumers who rely on these services for their health needs.

The probe also examines whether CVS is using audits to claw back payments from independent pharmacies or enforcing contracts that could harm small businesses. These practices, if proven, could have significant implications for the pharmaceutical industry and the broader healthcare ecosystem.

The Bigger Picture

Florida’s action against CVS Health mirrors similar efforts in other states where officials are challenging the dominance of vertically integrated PBMs. Arkansas and Tennessee have already implemented laws aimed at preventing PBMs from owning or being affiliated with pharmacies within their borders. However, these efforts have faced legal hurdles; a federal court blocked the Arkansas law last summer, and major PBMs like Caremark and Express Scripts, along with the Pharmaceutical Care Management Association (PCMA), are suing to challenge Tennessee’s new PBM law.

The pushback from industry leaders underscores the high stakes involved in regulating pharmacy benefit managers. These entities play a crucial role in managing prescription drug benefits for millions of Americans, but their vertical integration has raised concerns about conflicts of interest and potential anticompetitive behavior.

As states continue to grapple with these issues, the outcome of Florida’s investigation could set a precedent for future regulatory actions. Uthmeier’s probe not only aims to protect consumers and small businesses but also seeks to ensure that the healthcare market remains transparent and fair.

The broader implications of this investigation extend beyond Florida, as it highlights the ongoing tension between industry consolidation and consumer protection in the pharmaceutical sector. As more states consider similar measures, the balance between fostering competition and maintaining a robust healthcare system will remain a critical policy issue.